Review
Medicine, Research & Experimental
Tong Wu, Zhenhua Tong, Tianshu Ren, Danni Xie, Xue Sun
Summary: This meta-analysis demonstrated that the use of erythropoiesis-stimulating agents (ESAs) increases the risk of mortality and thrombo-vascular adverse events in breast cancer patients, while effectively improving anemia symptoms and reducing transfusion requirements.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Medicine, General & Internal
Seok Hui Kang, Bo Yeon Kim, Eun Jung Son, Gui Ok Kim, Jun Young Do
Summary: This study aimed to evaluate the difference in patient survival according to the type of erythropoiesis-stimulating agent (ESA) treatment in the Korean hemodialysis population. The study analyzed retrospective data from a national HD quality assessment program and claims in Korea. The results showed that the MR group had comparable or better patient survival than the EP and DP groups in the multivariate analysis. However, it was difficult to determine the exact factors leading to the better patient survival in the MR group.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Hematology
Sai Pan, De-Long Zhao, Ping Li, Xue-Feng Sun, Jian-Hui Zhou, Kang-Kang Song, Yong Wang, Li-Ning Miao, Zhao-Hui Ni, Hong-Li Lin, Fu-You Liu, Ying Li, Ya Ni He, Nian-Song Wang, Cai-Li Wang, Ai-Hua Zhang, Meng-Hua Chen, Xiao-Ping Yang, Yue-Yi Deng, Feng-Min Shao, Shu-Xia Fu, Jing-Ai Fang, Guang-Yan Cai, Xiang-Mei Chen
Summary: The study revealed that Chinese hemodialysis patients administered high dosages of erythropoiesis-stimulating agents had a significantly increased risk of mortality, and patients with a higher degree of resistance to these agents also faced a higher risk of all-cause mortality.
BLOOD PURIFICATION
(2022)
Article
Environmental Sciences
Natalino Salgado Filho, Joyce Santos Lages, Dyego Jose de Araujo Brito, Elton John Freitas Santos, Alcione Miranda dos Santos, Francival Leite de Souza, Vinicius Giuliano Goncalves Mendes, Giselle Andrade dos Santos Silva, Erika Cristina Ribeiro de Lima Carneiro, Monique Pereira Rego Muniz, Gyl Eanes Barros Silva, Ricardo de Castro Cintra Sesso
Summary: This study found a high variability in hemoglobin levels among end-stage renal disease patients, which was not significantly associated with mortality. Age, erythropoietin dose, and transferrin saturation were identified as factors associated with higher mortality rates.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2021)
Article
Health Care Sciences & Services
Wen-Sheng Liu, Chien-Hung Lin, Ann Charis Tan, Yen-Ting Lai, Tsung-Yun Liu, Hsiang-Lin Chan, Szu-Yuan Li, Chun-Fan Chen, Yung-Tai Chen, Tz-Heng Chen, Fan-Yu Chen, Yang Ho, Han-Hsing Tsou, Chih-Ching Lin
Summary: This study investigated the impact of inflammation and environmental toxins on the erythropoietic response of hemodialysis patients receiving ESA treatment. The results suggest that age, glucose, chloride, liver function, and inflammation are associated with the frequency of fixed CERA dosage administration.
Article
Urology & Nephrology
Cheng-Wen Yang, Mei-Chen Lin, Kai-Hsiang Shu, Kuei-Tung Tung, Wan-Chuan Tsai, Ju-Yeh Yang, Mei-Fen Pai, Hon-Yen Wu, Yen-Ling Chiu, Yu-Sen Peng, Shih-Ping Hsu, Shi-Heng Wang, Szu-Yu Pan
Summary: The study analyzed the association between ESA dose and mortality in 304 hemodialysis patients in Taiwan. It found that an extremely low dose of ESA (<15,000 U) was associated with increased mortality risk while a higher dose (25,001-43,000 U) showed no significant increase in mortality risk compared to a moderate dose (15,000-25,000 U). Further research is needed to confirm this association.
AMERICAN JOURNAL OF NEPHROLOGY
(2023)
Article
Oncology
Mette Kalager, Hans-Olov Adami, Pernilla Lagergren, Karen Steindorf, Paul W. Dickman
Summary: The European Academy of Cancer Sciences has set goals to improve cancer control in Europe, aiming to reach a 75% overall cancer-specific 10-year survival rate and a decline in overall cancer mortality rates. The study proposes standardized population-based measures for assessing the cancer burden and suggests novel approaches to improve quality of life assessment.
MOLECULAR ONCOLOGY
(2021)
Article
Urology & Nephrology
David A. Goodkin, Junhui Zhao, Aleix Cases, Masaomi Nangaku, Angelo Karaboyas
Summary: This study investigated factors associated with erythropoiesis-stimulating agent (ESA) hyporesponsiveness, including its duration, frequency, and variation across countries. The findings showed that most patients changed their ESA Resistance Index (ERI) quintile within 4 months, with only a small percentage remaining in the top quintile throughout the 12-month follow-up. A significant proportion of patients experienced an upper-quintile ERI at some point, and the median duration of a new episode of ESA resistance was 2 months. Factors associated with high ERI included catheter hemoaccess, elevated C-reactive protein, lower transferrin saturation, lower serum albumin concentration, and recent hospitalization. ERI values were highest in the USA, Italy, and Mideastern nations, and lowest in Russia and Japan.
AMERICAN JOURNAL OF NEPHROLOGY
(2022)
Review
Physiology
Sanja Vignjevic Petrinovic, Aleksandra Jaukovic, Maja Milosevic, Diana Bugarski, Mirela Budec
Summary: Cancer-related anemia (CRA) is a common disorder that negatively affects the quality of life and prognosis in cancer patients. Stress erythropoiesis (SE) plays a pivotal role in CRA, but chronic SE may lead to ineffective erythropoiesis, worsening the condition. Therefore, there is an urgent need to control ineffective erythropoiesis in cancer patients and develop personalized treatment strategies for CRA management.
FRONTIERS IN PHYSIOLOGY
(2022)
Review
Transplantation
Francesco Locatelli, Lucia Del Vecchio, Luca De Nicola, Roberto Minutolo
Summary: Erythropoiesis-stimulating agents (ESAs) are effective drugs for correcting and maintaining hemoglobin levels, but their use at high doses may increase the risk of cardiovascular adverse events, mortality, and cancer. The different ESA molecules have varying efficacy and safety profiles, with limited evaluation on the mortality and morbidity risks associated with their use. Recent studies have shown conflicting results on the safety of different types of ESAs, with randomized clinical trials providing more reliable evidence. The introduction of prolyl-hydroxylase domain (PHD) inhibitors as a new class of ESAs poses additional complexity due to their unique mechanisms and potential effectiveness in certain patient populations.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2021)
Article
Multidisciplinary Sciences
Pei-Hua Yu, Ming-Yen Lin, Yi-Wen Chiu, Jia-Jung Lee, Shang-Jyh Hwang, Chi-Chih Hung, Hung-Chun Chen
Summary: CKD stage 1-4 patients with normal TSAT but low serum iron are still at risk for anemia.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
Russell Lewis, Jan Philipp Bewersdorf, Amer M. Zeidan
Summary: For patients with LR-MDS, the goal is to alleviate symptoms and reduce transfusion burden associated with anemia. In addition to traditional treatments like supportive transfusions and ESAs, there are other therapeutic options available, such as luspatercept and lenalidomide, with novel agents like imetelstat and roxadustat in development.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Y. Escobar alvarez, R. de las Penas Bataller, J. Perez Altozano, S. Ros Martinez, A. Sabino alvarez, A. Blasco Cordellat, E. Brozos Vazquez, J. Corral Jaime, I. Garcia Escobar, C. Beato Zambrano
Summary: Anaemia is characterized by low haemoglobin levels and is common in cancer patients, leading to fatigue and reduced quality of life. Basic diagnostic tests are recommended and treatment options include erythropoiesis-stimulating agents, iron supplements, and blood transfusions.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2021)
Article
Oncology
Abigail Ludwigson, Victoria Huynh, Sara Myers, Karen Hampanda, Nicole Christian, Gretchen Ahrendt, Karina Romandetti, Sarah Tevis
Summary: Breast cancer patients exhibit anxiety towards COVID-19 infection and potential care modifications. Further investigation will provide insights for interventions to improve psychosocial outcomes for patients and the telehealth experience.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Urology & Nephrology
Rajiv Agarwal, Sanjeev Anand, Kai-Uwe Eckardt, Wenli Luo, Patrick S. Parfrey, Mark J. Sarnak, Christine M. Solinsky, Dennis L. Vargo, Wolfgang C. Winkelmayer, Glenn M. Chertow
Summary: Anemia is common in chronic kidney disease (CKD) and has negative impacts on quality of life and cardiovascular outcomes. Current standard of care for anemia in CKD requires chronic injections, making it less accessible to certain patients. Safety concerns have also been raised regarding the use of erythropoiesis-stimulating agents. The orally active vadadustat may offer advantages over these agents by activating endogenous erythropoietin production.
AMERICAN JOURNAL OF NEPHROLOGY
(2023)
Article
Cell Biology
E. Del Poggetto, M. Tanturli, N. Ben-Califa, A. Gozzini, I. Tusa, G. Cheloni, I. Marzi, M. G. Cipolleschi, Y. Kashman, D. Neumann, E. Rovida, P. Dello Sbarba
Article
Endocrinology & Metabolism
Martina Rauner, Kristin Franke, Marta Murray, Rashim Pal Singh, Sahar Hiram-Bab, Uwe Platzbecker, Max Gassmann, Merav Socolovsky, Drorit Neumann, Yankel Gabet, Triantafyllos Chavakis, Lorenz C. Hofbauer, Ben Wielockx
JOURNAL OF BONE AND MINERAL RESEARCH
(2016)
Article
Multidisciplinary Sciences
Naamit Deshet-Unger, Sahar Hiram-Bab, Yasmin Haim-Ohana, Moshe Mittelman, Yankel Gabet, Drorit Neumann
SCIENTIFIC REPORTS
(2016)
Article
Oncology
Naamit Deshet-Unger, Howard S. Oster, Sara Prutchi-Sagiv, Nir Maaravi, Nataliya Golishevski, Drorit Neumann, Moshe Mittelman
Article
Pediatrics
Rachel Gavish, Salmas Watad, Nathalie Ben-Califa, Ori Jacob Goldberg, Orly Haskin, Miriam Davidovits, Gili Koren, Yafa Falush, Drorit Neumann, Irit Krause
PEDIATRIC NEPHROLOGY
(2018)
Article
Multidisciplinary Sciences
Dafna Gilboa, Yasmin Haim-Ohana, Naamit Deshet-Unger, Nathalie Ben-Califa, Sahar Hiram-Bab, Debby Reuveni, Ehud Zigmond, Max Gassmann, Yankel Gabet, Chen Varol, Drorit Neumann
SCIENTIFIC REPORTS
(2017)
Article
Biochemistry & Molecular Biology
Albert Kolomansky, Sahar Hiram-Bab, Nathalie Ben-Califa, Tamar Liron, Naamit Deshet-Unger, Moshe Mittelman, Howard S. Oster, Martina Rauner, Ben Wielockx, Drorit Neumann, Yankel Gabet
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Article
Hematology
Howard S. Oster, Moran Gvili Perelman, Albert Kolomansky, Drorit Neumann, Moshe Mittelman
Summary: This study revealed an association between ESA treatment for anemia and lower blood glucose levels in hematologic patients, especially in diabetic patients and those on steroid treatment. Further research with both diabetic and nondiabetic patients is needed to clarify this association and its underlying mechanisms.
ACTA HAEMATOLOGICA
(2021)
Article
Immunology
Albert Kolomansky, Irit Kaye, Nathalie Ben-Califa, Anton Gorodov, Zamzam Awida, Ofer Sadovnic, Maria Ibrahim, Tamar Liron, Sahar Hiram-Bab, Howard S. Oster, Nadav Sarid, Chava Perry, Yankel Gabet, Moshe Mittelman, Drorit Neumann
FRONTIERS IN IMMUNOLOGY
(2020)
Article
Cell Biology
Edo Cohen-Karlik, Zamzam Awida, Ayelet Bergman, Shahar Eshed, Omer Nestor, Michelle Kadashev, Sapir Ben Yosef, Hussam Saed, Yishay Mansour, Amir Globerson, Drorit Neumann, Yankel Gabet
Summary: The current manual methods used to study osteoclast differentiation are cumbersome, time-consuming, and subject to operator bias. Therefore, replacing this with a completely automated process using computer vision algorithms can improve efficiency and reduce human bias.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Zamzam Awida, Almog Bachar, Hussam Saed, Anton Gorodov, Nathalie Ben-Califa, Maria Ibrahim, Albert Kolomansky, Jennifer Ana Iden, Liad Graniewitz Visacovsky, Tamar Liron, Sahar Hiram-Bab, Michael Brines, Yankel Gabet, Drorit Neumann
Summary: The study shows that Cibinetide (CIB) can increase bone density and inhibit osteoclastogenesis in mice, suggesting it as a potential candidate for the treatment of bone loss.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Zamzam Awida, Sahar Hiram-Bab, Almog Bachar, Hussam Saed, Dan Zyc, Anton Gorodov, Nathalie Ben-Califa, Sewar Omari, Jana Omar, Liana Younis, Jennifer Ana Iden, Liad Graniewitz Visacovsky, Ida Gluzman, Tamar Liron, Bitya Raphael-Mizrahi, Albert Kolomansky, Martina Rauner, Ben Wielockx, Yankel Gabet, Drorit Neumann
Summary: This study demonstrates that EPOR in the monocytic lineage is at least partially responsible for the effect of EPO on bone loss.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell & Tissue Engineering
Martina Rauner, Marta Murray, Sylvia Thiele, Deepika Watts, Drorit Neumann, Yankel Gabet, Lorenz C. Hofbauer, Ben Wielockx
Summary: High levels of erythropoietin (Epo) can be harmful to bone health in adult organisms, and EpoR in osteoprogenitor cells plays a crucial role in regulating osteoblast function and osteoblast-mediated osteoclastogenesis.
Review
Biochemistry & Molecular Biology
Sahar Hiram-Bab, Drorit Neumann, Yankel Gabet
Article
Medicine, Research & Experimental
Naamit Deshet-Unger, Albert Kolomansky, Nathalie Ben-Califa, Sahar Hiram-Bab, Dafna Gilboa, Tamar Liron, Maria Ibrahim, Zamzam Awida, Anton Gorodov, Howard S. Oster, Moshe Mittelman, Martina Rauner, Ben Wielockx, Yankel Gabet, Drorit Neumann
